A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies March 15, 2018 Type of Cancer Multiple Myeloma Sponsor Sanofi Aventis Protocol Number TED10893 To Learn More Call (201)-510-0950
